GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope
GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals. The drug in question is Boston Pharma’s lead asset,...
View ArticleSK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M
Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics: SK, Carlyle offer more upfront cash to bluebird bio shareholders:...
View ArticleFDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer
The FDA approved a new antibody-drug conjugate from AbbVie on Wednesday to treat patients with certain kinds of lung cancer. Regulators granted accelerated approval to telisotuzumab vedotin in...
View ArticleSanofi touts $20B investment in US over five years
Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several pharma companies. The company said Wednesday that the investment includes...
View ArticleEx-FDA chief Robert Califf thinks RFK Jr.'s vaccine opinions are relevant
HHS Secretary Robert F. Kennedy Jr. told a House committee Wednesday morning that he believed his opinions on vaccines were “irrelevant,” prompting a rebuke from a former top US health official. The...
View ArticleRFK Jr. defends HHS staff cuts at two congressional hearings
HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and planned overhaul of the agency that’s expected to shrink the workforce by 20,000...
View ArticleHengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong...
Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China's leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars ($1.2 billion) from its proposed float on...
View ArticleBiohaven stock sinks on three-month delay for neuro drug's FDA approval decision
Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy troriluzole and will also require an advisory committee meeting to review the drug....
View ArticleMerck KGaA Q1 earnings: Tariff surcharge for US customers will continue
Despite pausing a tariff surcharge for China-based clients, Merck KGaA will carry on with adding an extra charge for US customers to account for President Donald Trump’s levies. “What we're doing is we...
View ArticleExclusive: Datavant will acquire Aetion, double life sciences team
The health tech company Datavant is acquiring Aetion, a rival in the real-world data space, Endpoints News exclusively reports. Datavant on Thursday plans to announce the deal, which will double the...
View ArticleAbundant Venture Partners teams up with 17 health systems to develop tech
Seventeen health systems have signed up for a venture firm to help them vet which health tech companies to adopt and invest in, as more hospitals look towards a more concierge-style approach to...
View ArticleEmpower Pharmacy allegedly used low-quality ingredients, skirted rules
A company that calls itself the US’ “largest and most advanced” compounding pharmacy — and whose business has exploded thanks to demand for popular weight loss drugs — has used poor-quality...
View ArticleAGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. AGC Biologics is partnering with Quell Therapeutics, the companies...
View ArticlePathos AI collects $365M to fuel data-driven oncology studies
Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so far this year. In the...
View ArticleBristol Myers CEO says America’s biopharma pole position is not guaranteed
NEW YORK — Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a “pivot point” as the Trump administration aims to remake the country’s institutions and...
View ArticleFDA warns Mayne Pharma over 'misleading' birth control pill claims
The FDA’s drug promotion office is calling out Australia's Mayne Pharma for making “false or misleading claims” about the benefits and risks of its birth control pill Nextstellis. The agency's
View ArticlePhiladelphia doctors treat infant with first custom CRISPR therapy that fixes...
PHILADELPHIA — Soon after Kyle Patrick Muldoon, Jr. was born in August 2024, his doctors knew something was wrong. KJ, as his parents call him, was too tired to feed, his ...
View ArticleEli Lilly teams up with RNA editing biotech for hearing loss
Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics. The Indianapolis drug giant and Seongnam, South Korea-based biotech will work...
View Article